First human tests: how chinese bodies handle new drug
NCT ID NCT06243198
Summary
This early-stage study tested the safety and how the body processes lebrikizumab in healthy Chinese volunteers. Twenty-four participants received a single injection of either the drug or a placebo. Researchers monitored side effects and measured how quickly the drug entered and left the bloodstream over about 21 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.